Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Open accessThe DOI matches its Crossref record; 128 of the 130 references it cites were found in a registry or an index.
Abstract
This paper discusses the current evidence from animal and human studies for a central role of inflammation in schizophrenia. In animal models, pre- or perinatal elicitation of the immune response may increase immune reactivity throughout life, and similar findings have been described in humans. Levels of pro-inflammatory markers, such as cytokines, have been found to be increased in the blood and cerebrospinal fluid of patients with schizophrenia. Numerous epidemiological and clinical studies have provided evidence that various infectious agents are risk factors for schizophrenia and other psychoses. For example, a large-scale epidemiological study performed in Denmark clearly showed that severe infections and autoimmune disorders are such risk factors. The vulnerability-stress-inflammation model may help to explain the role of inflammation in schizophrenia because stress can increase pro-inflammatory cytokines and may even contribute to a chronic pro-inflammatory state. Schizophrenia is characterized by risk genes that promote inflammation and by environmental stress factors and alterations of the immune system. Typical alterations of dopaminergic, serotonergic, noradrenergic, and glutamatergic neurotransmission described in schizophrenia have also been found in low-level neuroinflammation and consequently may be key factors in the generation of schizophrenia symptoms. Further support for the relevance of a low-level neuroinflammatory process in schizophrenia is provided by the loss of central nervous system volume and microglial activation demonstrated in neuroimaging studies. Last but not least, the benefit of anti-inflammatory medications found in some studies and the intrinsic anti-inflammatory and immunomodulatory effects of antipsychotics provide further support for the role of inflammation in this debilitating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence of altered inflammation-related markers across psychiatric conditions [6–8], along with reports of anti-inflammatory effects from psychotropic medications [9, 10] and the ameliorative impact of anti-inflammatory drugs on psychiatric symptoms [11–14], suggests a strong link between abnormal inflammatory responses and major psychiatric disorders.”
From Inflammatory ratios as predictors of length of hospitalization in psychiatric patients: A multicenter study (2025) · doi:10.1007/s00406-025-02033-9 · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A growing body of evidence suggests that immune dysfunction and inflammation have been considered to play important roles in the pathogenesis of SCZ and BD (11, 12).”
From Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Changes of some inflammation-related factors (IRFs) have been intensively studied and reviewed in relation to psychiatric disorders1–9.”
From Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses (2019) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Recent evidence suggests the involvement of the immune system in several psychiatric conditions [203–205]; one of the most studied in this respect is depression [206–208].”
From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [203]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murphy, K., & Weaver, C. (2016) · W.W. Norton eBooks · doi:10.1201/9781315533247 · Cited by 2,258
Vulnerability: A new view of schizophrenia.
Zubin, J., & Spring, B. (1977) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.86.2.103 · Cited by 1,992
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Maternal Immune Activation Alters Fetal Brain Development through Interleukin-6
Smith, S. E. P., Li, J., Garbett, K., Mirnics, K., & Patterson, P. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2178-07.2007 · Cited by 1,605
Serologic Evidence of Prenatal Influenza in the Etiology of Schizophrenia
Brown, A. S., Begg, M. D., Gravenstein, S., Schaefer, C. A., Wyatt, R. J., Bresnahan, M., Babulas, V. P., & Susser, E. S. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.774 · Cited by 1,053
The current status of the dopamine hypothesis of schizophrenia
CARLSSON, A. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90012-7 · Cited by 958
Neuropharmacology of quinolinic and kynurenic acids.
Stone, T. W. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00441-7 · Cited by 948
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862
Cited by
Items 601–648 of 648
Maslennikova, A. V., Martynova, O., & Portnova, G. V. (2026) · Studies in computational intelligence · doi:10.1007/978-3-032-13592-6_7
Beerwala, F. A., Kolambkar, S. V., Patil, V. S., Karikazi, A., Khatib, N. A., Harish, D. R., & Roy, S. (2026) · Energy Nexus · doi:10.1016/j.nexus.2026.100636
Fan, Y., Chen, J., Liu, L., Zhang, C., Guo, J., Chen, H., & Yang, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.06.704308
Fujita, K., Sugimoto, Y., Aratake, R., Yoshimoto, T., Kawai, M., Fukatsu, T., Mori, Y., Nishihara, M., & Miyata, J. (2026) · Annals of General Psychiatry · doi:10.1186/s12991-026-00640-x
“Furthermore, microglial activation and alterations in neuroplasticity have been implicated in both acute exacerbations and progressive disease processes in schizophrenia [27], and may be related to variability in antipsychotic treatment responsiveness [28].”
Weerasekera, A., Zhou, S., Wang, C., Qiu, Z., Stein, A., Ameer, M., Chouinard, V., Shinn, A. K., Lewandowski, K. E., Murphy, M., et al. (2026) · Human Brain Mapping · doi:10.1002/hbm.70479
“…and early-onset disease-related processes, such as aberrant synaptic pruning (Sekar et al. 2016), oxidative stress (Steullet et al. 2017; Fraguas et al. 2019) or neuroinflammation (Muller 2018; Najjar and Pearlman 2015) that precede the more pronounced midlife divergence seen in chronic illness.”
Zhang, J., Shen, N., Wang, P., Qiu, J., Luo, Y., Ding, Y., Liu, C., Jin, Y., Zhao, N., Cong, G., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8104089/v1
Altunsu, D., & Lizano, P. L. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106521
The Eph-ephrin system in neuropsychiatric and neurodevelopmental disorders
Bordignon, A., Manduca, J. D., & Perreault, M. L. (2026) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn-2025-0168 · Cited by 2
Braun, D., & Olmer, A. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1771815
Shen, Y., Wang, D., & Li, Z. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1790346
Сергеевна, Ш. Е., Sitnikova, E. O., & Filonenko, E. V. (2026) · Психология и Психотехника · doi:10.7256/2454-0722.2026.1.75051
Plasma proteome profiling identifies novel biomarkers and predictors for schizophrenia
Wu, S., Guo, X., Jia, T., Sun, Z., Yu, G., Ouyang, Y., Kou, C., & Bai, W. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04017-2
Aslan, M., Kaşıkçı, H. Ö., & İzci, F. (2026) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.26.1455
Dyne, A. V., Wu, T., Adamowicz, D. H., Irwin, M. R., Tu, X. M., Lee, E., & Eyler, L. T. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106592
Cassol, G., Souza, M. A., & Fiorin, F. D. S. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150344
Yolken, R. H., Dickerson, F., Hulett, T. W., Almodovar2, R. R., & Splan, V. W. (2026) · Research Square · doi:10.21203/rs.3.rs-9005269/v1
Sex-specific alterations of niacin flush pathway biomarkers in schizophrenia
Hsieh, K.-Y., Chiu, C.-W., Lin, J.-J., Tseng, H.-H., Huang, C.-C., Wang, T.-Y., Chen, P.-S., Yao, C.-Y., Jang, F.-L., Chang, W.-H., et al. (2026) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2026.107897
Mezquida, G., Pérez‐Ramos, A., Guasch-Capella, N., Forte, M. F., Parellada, M., Amoretti, S., Serra‐Navarro, M., Galvañ, J., Cuesta, M. J., Mané, A., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112859
Molecular adaptations of activated T-cells in an inflammation-associated schizophrenia sub-groupPreprint
Salem, D., O’Hara-Payne, R. K., Clark, S., Cortes-Gutierrez, M., Singh, N. J., Roche, D. J. O., Kelly, D. L., & Ament, S. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.22.727194
Forrer, S., Delavari, F., Sandini, C., Ville, D. V. D., & Eliez, S. (2026) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2026.100768
“2DS In 22q11DS, vulnerabilities in blood-brain barrier integrity (64) and cellular metabolism (65–68) may heighten susceptibility to neuroinflammation, which can disrupt glial regulation and thus the timing of maturational processes (69,70).”
Li, J., Ma, X., Liu, J., Xu, W., Zhang, X., Liang, F., & Dou, Y. (2026) · Psychoradiology · doi:10.1093/psyrad/kkag023
“These manifestations are closely associated with chronic low-grade inflammation, oxidative stress, and regional imbalances in energy metabolism (Müller, 2018 ; Purcell et al. , 2023 ; Huang et al. , 2025 ).”
Yalçın, M., & Tuncer, M. C. (2026) · Diagnostics · doi:10.3390/diagnostics16121905
Sharma, U., Shashikala, G., Manjunatha, P. M., Uday, R., Singh, Y., Janadri, S., Vada, S., & Haribabu, T. (2026) · Learning and Motivation · doi:10.1016/j.lmot.2026.102285
Disease severity across psychiatric disorders is linked to pro-inflammatory cytokine
Solomon, P., Budde, M., Kohshour, M. O., Adorjan, K., Heilbronner, M., Navarro-Flores, A., Papiol, S., Reich‐Erkelenz, D., Schulte, E., Senner, F., et al. (2025) · MPG.PuRe (Max Planck Society)
Genetic Analysis of the HSPA1A, HSPA1B, and HSPA1L Genes in Patients with Schizophrenia from Taiwan
Wang, Y. J., Hsu, S.-H., Tsai, H.-Y., & Cheng, M.-C. (2026) · Genes · doi:10.3390/genes17070727
“There is evidence linking neuroinflammation—driven by the activation of microglia and astrocytes—to the pathophysiology of schizophrenia [4,31].”
From Perinatal Stress to Schizophrenia: The Emerging Role of Glial Pathology
Sarkar, T., Patro, N., & Patro, I. K. (2026) · Annals of Neurosciences · doi:10.1177/09727531261445799
“95,98”
Klein, H. C., Guest, P. C., Benros, M. E., Tunvirachaisakul, C., Scheiber, C., Maes, M. H. J., Yolken, R., Bechter, K., & Steiner, J. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1833449
Plasma exosomal microRNA profiles associated with agitation symptoms in schizophrenia
Ling, Y., Wang, Y., Zhu, R., Tang, Y., Tao, R., Li, Y., & Sui, Y. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08459-2
“Neuropathological and neuroimaging studies have revealed activated microglia and regional gray matter volume loss in the prefrontal cortex [17].”
Esfahani, S. S., Mahdinia, E., Dehkhodaei, S., Oumali, N. A., Taherkhani, S., & Rafaiee, R. (2026) · Pain Management · doi:10.1080/17581869.2026.2713532
Soluble urokinase plasminogen activator receptor – What are the clinical potentials in psychiatry?
Huber, F. G., Kristensen, M. W. P., Nielsen, M. Ø., Vang, T., & Nielsen, J. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101329
“Even though no firm conclusion can be made on which inflammatory processes are dominating the disorders, both major depressive disorder (MDD) and schizophrenia have been linked to various inflammatory processes (Muller, 2018; Reus et al., 2023).”
Liao, F., Zhong, Q., Lu, R., Liang, T., Lan, W., Zhong, Z., Shen, B., Long, J., & Su, L. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-026-02339-2
Embleton, K., Bennett, S. D., MacCabe, J. H., & Egerton, A. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101342
“There is increasing evidence that inflammatory mechanisms play an important role in the aetiology of schizophrenia (Muller, 2018).”
Gao, X., Wang, T., He, Y., Huang, X., Song, Z., Lv, M., Zhong, Z., Huang, Y., Su, L., & Long, J. (2026) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2026.120756
Wu, Y., Gasparrini, A., Su, B., Talifu, Z., Mukadam, N., Tian, Y., Warren‐Gash, C., & Zheng, X. (2026) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2026.120733
Liu, W., Xia, X., Hong, Z., Deng, Z., Zhu, F., Zhang, K., Kang, S., Wei, Q., Tao, J., & Li, L. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.09.031
Tan, M., Hu, Y.-Y., Du, X.-Y., Yang, Y.-R., Hong, R., Zhang, Z.-J., & Li, R.-T. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122413
Ku, B. S., Xu, Y., Goldsmith, D. R., Sawyers, C. K., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Carrión, R. E., Keshavan, M. S., et al. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.107036
Long, X., Zhang, M., Cheng, P., Wang, F., Wang, Y., Liu, X., Huang, W., Chen, G., 刘哲宁, Yang, J., et al. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.09.024
Shinohara, R. C., Ishikawa, S., Matsumoto, R., Ito, K., Tonosaki, M., Matsuyama, S., Ohgidani, M., Koga, M., Hashimoto, N., Kusumi, I., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70697
Sun, D., Zhang, C., Hou, M., & Zhao, H. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06253-5
“Pro-inflammatory Pro-inflammatory cytokines, in particular, are suggested to disrupt critical processes such as neurodevelopment, synaptic plasticity, and neurotransmitter homeostasis, contributing to the onset and progression of SCZ [10, 11].”
Epigenetics processes involved in schizophrenia and antipsychotic treatment
MALIK, K., Davies, S. J. C., RAVINDRAN, N., & LUCA, V. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19043-8.00024-4
Increased Serum TNF‐α Levels Are Associated With Generalized Anxiety Disorder: A Case‐Control Study
Nur, T. A., Ahmed, Z. L., Emon, F. A., Urmi, T. J., Parves, M. M., Islam, M. R., & Nahar, Z. (2026) · Health Science Reports · doi:10.1002/hsr2.73277
“Various research indicated the role of neuroinflammation in the etiology of different psychiatric disorders [16–19].”
Air mass advection and immune dysregulation in schizophrenia: an exploratory pilot study
Modzelewski, S., Oracz, A. J., Suprunowicz, M., Śladewska, A., Froń, O., Kosidło, J. W., Matowicka-Karna, J., & Waszkiewicz, N. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1950134
Kaur, M. K. K., Allahbadia, M. G., & MD, D. M. S. (2025) · Obesity Research - Open Journal · doi:10.17140/oroj.2025.v11.i01.pp19-45.1417
BindingDB Entry 50018428: Progress in mechanistically novel treatments for schizophrenia.
BindingDB (2024) · UC San Diego · doi:10.7270/q2fr01sz
C-Reactive Protein Levels and Elevations in Schizophrenia: The Central Role of Body Mass Index
Yolken, R. H., Khan, S., Origoni, A. E., Rowe, K. C., Katsafanas, E., Mukhtar, F., Calahatian, A. T., Yang, S., & Dickerson, F. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag152
Metadata
- Authors
- Müller, N.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Müller, Norbert
- ORCID
- Müller, Norbert
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-10
- Volume
- 44
- Issue
- 5
- Pages
- 973-982
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC6101562
- OpenAlex
- W2888647009
- Cited by
- 648
- References
- 130
- Citations by year
- 2026: 62 · 2025: 88 · 2024: 92 · 2023: 116 · 2022: 102 · 2021: 98 · 2020: 62 · 2019: 18 · 2018: 9
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Schizophrenia Bulletin (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- schizophrenia, neuroinflammation
- MeSH terms
- Animals, Anti-Inflammatory Agents, Humans, Inflammation, Schizophrenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.